Lauren Hirsch1,2,3, Jaeun Yang4, Lauren Bresee1,3,5, Nathalie Jette1,2,4,3, Scott Patten1,2,4,3, Tamara Pringsheim6. 1. Department of Community Health Sciences, University of Calgary, Calgary, AB, Canada. 2. Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada. 3. O'Brien Institute of Public Health, University of Calgary, Calgary, AB, Canada. 4. Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada. 5. Canadian Agency for Drugs and Technologies in Health, Ottawa, ON, Canada. 6. Department of Clinical Neurosciences, Psychiatry, Pediatrics and Community Health Sciences, University of Calgary, Mathison Centre for Mental Health Research and Education, 3280 Hospital Drive NW, Calgary, AB, T2N 4Z6, Canada. tmprings@ucalgary.ca.
Abstract
INTRODUCTION: There is strong evidence from randomized controlled trials (RCTs) that second-generation antipsychotic (SGA) medications are associated with metabolic adverse events. However, with the recent increases in the use of SGAs worldwide and frequent off-label use, it is unclear whether these associations are generalizable to populations beyond those included in RCTs. OBJECTIVES: This review aims to characterize the impact of SGAs on the population through a systematic review of population-based studies of SGA users. Studies could examine the use of any SGA medication and any comparator group. Studies also needed to include at least one metabolic outcome such as type 2 diabetes mellitus, dyslipidemia, obesity, hypertension, or metabolic syndrome. METHODS: A systematic search process was used to identify studies for inclusion in this review. Included studies had to be population-based studies of users of any SGA medication with at least one reported metabolic outcome. Study quality was also assessed using the AMSTAR tool, and evidence was synthesized by both metabolic outcome and specific SGA medication. RESULTS: In total, 15 studies were included in this review. Type 2 diabetes mellitus was the most frequently reported outcome; clozapine and olanzapine were most strongly associated with type 2 diabetes mellitus. Evidence was mixed for a moderate association between type 2 diabetes mellitus and risperidone or quetiapine. Few studies examined other metabolic outcomes, and therefore it is difficult to estimate the true effect in the population. DISCUSSION: Population-based evidence for other SGAs and metabolic outcomes was limited. However, clozapine and olanzapine were consistently more strongly associated with metabolic adverse events than were other SGAs currently available.
INTRODUCTION: There is strong evidence from randomized controlled trials (RCTs) that second-generation antipsychotic (SGA) medications are associated with metabolic adverse events. However, with the recent increases in the use of SGAs worldwide and frequent off-label use, it is unclear whether these associations are generalizable to populations beyond those included in RCTs. OBJECTIVES: This review aims to characterize the impact of SGAs on the population through a systematic review of population-based studies of SGA users. Studies could examine the use of any SGA medication and any comparator group. Studies also needed to include at least one metabolic outcome such as type 2 diabetes mellitus, dyslipidemia, obesity, hypertension, or metabolic syndrome. METHODS: A systematic search process was used to identify studies for inclusion in this review. Included studies had to be population-based studies of users of any SGA medication with at least one reported metabolic outcome. Study quality was also assessed using the AMSTAR tool, and evidence was synthesized by both metabolic outcome and specific SGA medication. RESULTS: In total, 15 studies were included in this review. Type 2 diabetes mellitus was the most frequently reported outcome; clozapine and olanzapine were most strongly associated with type 2 diabetes mellitus. Evidence was mixed for a moderate association between type 2 diabetes mellitus and risperidone or quetiapine. Few studies examined other metabolic outcomes, and therefore it is difficult to estimate the true effect in the population. DISCUSSION: Population-based evidence for other SGAs and metabolic outcomes was limited. However, clozapine and olanzapine were consistently more strongly associated with metabolic adverse events than were other SGAs currently available.
Authors: Diana I Brixner; Qayyim Said; Patricia K Corey-Lisle; A Vickie Tuomari; Gilbert J L'italien; William Stockdale; Gary M Oderda Journal: Ann Pharmacother Date: 2006-03-28 Impact factor: 3.154
Authors: Priya Khanna; Tao Suo; Katja Komossa; Huaixing Ma; Christine Rummel-Kluge; Hany George El-Sayeh; Stefan Leucht; Jun Xia Journal: Cochrane Database Syst Rev Date: 2014-01-02
Authors: Domenico De Berardis; Gabriella Rapini; Luigi Olivieri; Domenico Di Nicola; Carmine Tomasetti; Alessandro Valchera; Michele Fornaro; Fabio Di Fabio; Giampaolo Perna; Marco Di Nicola; Gianluca Serafini; Alessandro Carano; Maurizio Pompili; Federica Vellante; Laura Orsolini; Giovanni Martinotti; Massimo Di Giannantonio Journal: Ther Adv Drug Saf Date: 2018-02-06
Authors: Jillian S Weissenrieder; Jeffrey D Neighbors; Richard B Mailman; Raymond J Hohl Journal: J Pharmacol Exp Ther Date: 2019-04-18 Impact factor: 4.030
Authors: Kenneth K C Man; Shih-Chieh Shao; Nathorn Chaiyakunapruk; Piyameth Dilokthornsakul; Kiyoshi Kubota; Junqing Li; Nobuhiro Ooba; Nicole Pratt; Anton Pottegård; Lotte Rasmussen; Elizabeth E Roughead; Ju-Young Shin; Chien-Chou Su; Ian C K Wong; Yea-Huei Kao Yang; Edward Chia-Cheng Lai Journal: Eur Child Adolesc Psychiatry Date: 2020-11-13 Impact factor: 4.785
Authors: Amber Edinoff; Natalie Wu; Charles deBoisblanc; Catherine Olivia Feltner; Mariah Norder; Vesela Tzoneva; Adam M Kaye; Elyse M Cornett; Alan D Kaye; Omar Viswanath; Ivan Urits Journal: Psychopharmacol Bull Date: 2020-09-14